ContraFect Corporation announced the following organizational changes effective October 1, 2016. Cara Cassino, M. D. has been promoted to Chief Medical Officer and Executive Vice President of Research and Development. She will provide leadership to all research and development functions. Dr. Cassino has served as Chief Medical Officer and Senior Vice President of Development at ContraFect since joining the company in September, 2015. Michael Messinger is promoted to Senior Vice President, Finance. In addition to his oversight of the finance and accounting functions at ContraFect, he will now also oversee investor and press relations activities. Mr. Messinger has served as Vice President, Finance at ContraFect since joining in November, 2012. Michael Wittekind, PhD, Chief Scientific Officer and Senior Vice President, Research will be leaving ContraFect to pursue opportunities closer to his primary residence in the Seattle area. To assist with a smooth leadership transition, Dr. Wittekind will continue to serve as a consultant to ContraFect.